Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
The govt has rolled out three schemes for promoting the manufacture of API
Drug formulations and biologics make impressive gains
It works as an adjunct to standard care based on robust clinical trials
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
India business is growing as per projections; whereas US business will bounce back soon.
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
